In this single-center, Phase I trial, researchers administered anti-CD7 chimeric antigen receptor (CAR) T cells, manufactured from either previous stem-cell transplantation donors or new donors, to patients with relapsed or refractory T-cell acute lymphoblastic leukemia, in single infusions at doses of 5 × 105 or 1 × 106 cells per kilogram of body weight.
[Journal of Clinical Oncology]
Sorry, but the selected Zotpress account can't be found.
